Aug. 1 at 4:43 PM
$TNGX 🚨 live short interest @ 50.48% 👀
• Market Cap:
$724M
• Enterprise Value:
$599M
• Outstanding Shares: ~108.4M
• Float: ~106.5M
• Est. Net Cash/Share:
$1.15 (with
$162M cash)
• Quarterly Burn: –
$41.7M → ~11.6 months runway
• Institutional Ownership: 98%
• Short Interest: 20.2%
Shelf
• May 2025 registration:
$400M capacity, full access (no baby restriction, exp 2028‑05‑21)
ATM Line
• May 2025 Jefferies ATM:
$100M capacity (registered & available)
-
$400M live shelf +
$100M ATM gives flexibility to raise equity as needed. No baby shelf means full liquidity access at current share price.
-No outstanding warrants or convertible securities disclosed—valuation reliant on pipeline progress rather than structured dilutive capital.
-Nearly 98% institutional ownership provides float stability, while 20% short interest indicates trader attention and volatility potential.
-Focused on synthetic-lethality biotech targeting PRMT5, with upcoming catalysts including TNG462 and TNG456 trials (e.g., pancreatic, lung, GBM)
